Clinical Efficacy Evaluation of a Continuous Glucose Monitoring-Guided Forecasting Algorithm to Mitigate Postbariatric Hypoglycemia: A Randomized Controlled Trial
Abstract
Postbariatric hypoglycemia (PBH) after Roux-en-Y gastric bypass predisposes to health risks and impaired quality of life. Given limited therapeutic options, we evaluated the efficacy of a continuous glucose monitoring (CGM)-guided forecasting algorithm to reduce PBH. In this randomized trial, 59 participants underwent a standardized meal test and were assigned to receive 5 g of glucose either upon the algorithm’s predictive alert (intervention, n = 32) or when plasma glucose declined below 3.0 mmol/L (control, n = 27). Hypoglycemia incidence (<3.0 mmol/L) was 31% in the intervention group and 44% in the control group (P = 0.30). Nadir glucose and time spent below 3.9 and 3.0 mmol/L did not differ significantly between groups. Extrapolation based on previously published glucose dose–response data suggests that increasing the preventive glucose dose to 10 g could reduce hypoglycemia incidence to 9%. While a 5 g preventive dose was insufficient, these simulations indicate that CGM-guided hypoglycemia forecasting warrants evaluation as an approach for reducing postprandial hypoglycemia in individuals with PBH.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 59 participants or records.
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- Therapeutic Potential of Mesenchymal Stem Cells (MSCs) and MSC-Derived Extracellular Vesicles for the Treatment of Spinal Cord Injury
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.